Matthew Lang - Aug 10, 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Business Officer
Signature
/s/ Matthew Lang
Stock symbol
LYEL
Transactions as of
Aug 10, 2023
Transactions value $
$0
Form type
4
Date filed
8/11/2023, 04:24 PM
Previous filing
Jul 20, 2023
Next filing
Feb 13, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +2.25M $0.00 2.25M Aug 10, 2023 Common Stock 2.25M $2.31 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares shall vest on July 1, 2024, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.